|
|
Vaccine Detail
|
WT1 247-261 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: WT1 247-261 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007059
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Potential HLA-DR promiscuous CD4+ T-cell epitopes were selected from the amino acid sequence of the WT1 using the algorithm tables for three HLA-DR alleles (DRB1*0101, DRB1*0401, and DRB1*0701). The peptides are synthetically made (Kobayashi et al., 2006).
- Description: This is for Leukemia Cancer, Lung Cancer and Breast Cancer. A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers (Kobayashi et al., 2006; NCIT_C104737).
|
| Host Response |
|
|
| References |
Kobayashi et al., 2006: Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer immunology, immunotherapy : CII. 2006; 55(7); 850-860. [PubMed: 16220325].
NCIT_C104737: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C104737]
|
|
